Health and Economic Burden of Obesity in Brazil

Ketevan Rtveladze¹, Tim Marsh¹, Laura Webber¹, Fanny Kilpi¹, David Levy², Wolney Conde³, Klim McPherson⁴, Martin Brown¹

¹ Micro Health Simulations, London, United Kingdom, ² Georgetown University, Washington, D. C., United States of America, ³ University of Sao Paulo, Sao Paulo, Brazil, ⁴ New College, Oxford, United Kingdom

Abstract

Introduction: Higher and lower-middle income countries are increasingly affected by obesity. Obesity-related diseases are placing a substantial health and economic burden on Brazil. Our aim is to measure the future consequences of these trends on the associated disease burden and health care costs.

Method: A previously developed micro-simulation model is used to project the extent of obesity, obesity-related diseases and associated healthcare costs to 2050. In total, thirteen diseases were considered: coronary heart disease, stroke, hypertension, diabetes, osteoarthritis, and eight cancers. We simulated three hypothetical intervention scenarios: no intervention, 1% and 5% reduction in body mass index (BMI).

Results: In 2010, nearly 57% of the Brazilian male population was overweight or obese (BMI ≥25 kg/m²), but the model projects rates as high as 95% by 2050. A slightly less pessimistic picture is predicted for females, increasing from 43% in 2010 to 52% in 2050. Coronary heart disease, stroke, hypertension, cancers, osteoarthritis and diabetes prevalence cases are projected to at least double by 2050, reaching nearly 34,000 cases of hypertension by 2050 (per 100,000). 1% and 5% reduction in mean BMI will save over 800 prevalence cases and nearly 3,000 cases of hypertension by 2050 respectively (per 100,000). The health care costs will double from 2010 ($5.8 billion) in 2050 alone ($10.1 billion). Over 40 years costs will reach $330 billion. However, with effective interventions the costs can be reduced to $302 billion by 1% and to $273 billion by 5% reduction in mean BMI across the population.

Conclusion: Obesity rates are rapidly increasing creating a high burden of disease and associated costs. However, an effective intervention to decrease obesity by just 1% will substantially reduce obesity burden and will have a significant effect on health care expenditure.

Introduction

NCDs, Nutrition and Obesity in Brazil

Non-communicable diseases (NCD) are increasingly recognised as the major health issue facing many governments [1]. In 2011, the United Nations (UN) convened the NCD summit to bring together governments to develop a global strategy to confront the problem. Particular attention focused on emerging economies where there has been a rapid increase in the burden of NCDs. A major concern underlying this increased burden is the trend toward increasing obesity [2]. Age-standardised NCD mortality in Brazil (625 per 100,000 people) less than that in Russia, Nigeria, India, and Tanzania (all >700 per 100,000). However, despite its rapid economic growth, Brazil’s NCD mortality is greater than that of the United Kingdom (UK) and Canada (both <100 per 100,000), and almost all other South American countries [3]. Like many nations, Brazil has seen a decline in mortality rates of coronary heart disease (CHD) rates [4] possibly due to improvements in treatment and reduced smoking rates. However, the CHD mortality rates are now expected to rise due to the recent increases in obesity rates [5] along with type-two diabetes those declining rates have been refrained [4]. In addition, Brazil also has one of the fastest aging populations [6] and populations generally gain weight as they age [7] and this could cause a significant challenge for policy makers to tackle burden caused by obesity and obesity in the nearest future.

Brazil has observed a rapid change in the weight profiles of its population, with the prevalence of obesity and overweight increasing partly as a result of the well documented nutrition transition [8], whereby diets move from consumption of fibre and carbohydrate into saturated fats and sugars [9,10], as well as increased sedentary behaviour [10]. Monteiro and colleagues (2010) classify three main groups of the food products according to the production processes: unprocessed food - first group; second group - processed food and third - ultra-processed, ready to eat/ ready to heat food products which have more saturated fat, sugars, sodium and less fibre comparing to the products from the group 1.

Citation: Rtveladze K, Marsh T, Webber L, Kilpi F, Levy D, et al. (2013) Health and Economic Burden of Obesity in Brazil. PLoS ONE 8(7): e68785. doi:10.1371/journal.pone.0068785

Copyright: © 2013 Rtveladze et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: GlaxoSmithKline provided a non-disclosory educational grant to fund this project (Grant number 27875780). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Authors KR, TM, LW, FK and MB are employed by Micro Health Simulations. GlaxoSmithKline provided funding for this study. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

E-mail: ketevan.rtveladze@heartforum.org.uk
overweight (25–29.9 kg/m²), and obesity (≥30 kg/m²) based on the WHO cut-offs [25]. BMI and Micro-simulation

Methods

BMI and Micro-simulation

A review of the epidemiological and academic literature was undertaken to determine the country-specific disease incidence, mortality (where applicable), survival or case-fatality rates and annual total medical costs for the following obesity-related 13 diseases: type 2 diabetes, coronary heart disease - CHD (ischemic heart disease [IHD] or myocardial infarction [MI]), stroke, hypertension, kidney, colorectal, oesophageal, endometrial, prostate, liver and gall bladder by age and sex. Disease Data Collection

For fatal diseases, the micro-simulation requires county specific disease incidence data. Prevalence data can be converted into incidence if necessary using DISMOD-II equations [28]. This converts the prevalence into incidence by dividing the prevalence rate by average duration of the illness, but can only be used for non-terminal diseases. For this project, we have carried out calculations to estimate the incidence of diabetes and hypertension with the following matrix equation where each column independently sums up to 1:

\[ p \] is the probability of being alive without disease \( d \), \( p_1(k) \) indicates the probability of being alive with disease \( d \) in year \( k \), and \( p_2(k) \) represents the probability of being dead in year \( k \). The probabilities of being alive with (state 0) or without the disease (state 1) and being dead (state 2) have been also assigned to the calculation as well as death statistics \( p_{d,k} \) (the probability of dying from disease \( d \) in year \( k \) (gender \( s \), age \( a_k \))) and \( p_{a_k} \) (the probability of dying from a cause other than disease \( d \) in year \( k \) (gender \( s \), age \( a_k \))).

Although Brazil has a high prevalence of CHD, recent incidence data was not found. Upon consulting experts in the Brazilian government and academic institutions, we used data from 1998 (Table 1) and this may result in overestimating the rates of CHD.

Cancer incidence and mortality data was acquired from the GLOBOCAN project 2008 [30]. Survival data was obtained only for breast, colorectal and endometrial cancers. For all 8 cancers we have used survival data from the US [19]. By using a proxy country, we probably overestimated the cancer survival since health care expenditure in US is the highest in the world, whereas Brazilian per capita health care spending is nearly 8 times lower than in US [31]. Because data on the incidence of knee osteoarthritis was not found, US data was used as a proxy. Since those rates reflect the obesity distribution of the US, we removed the effect of BMI distribution by extracting the rates of healthy individuals. We then use Brazil’s obesity rates to refine the rates.

We encountered multiple drawbacks during the review process of Brazil-specific cost estimates. We have based our projections on a various scientific articles with different methods of cost calculations. Some of them have only calculated cost of hospitalization [Sichieri 2007] [32], some have calculated only cost of new cases [33]. All in all, we were able to obtain cost of diabetes [34], CHD [32], stroke [32], hypertension [35], breast cancer and colorectal cancer [33] for Brazil (Table 1 and Table S2 in File S2). We were unsuccessful in obtaining the costs of the
remaining six cancers and knee osteoarthritis therefore these seven diseases have been omitted from cost projections. All the costs obtained were in USD but varied in years; therefore, the costs have been inflated for year 2010 to be uniform during the obtained were in USD but varied in years; therefore, the costs have been inflated for year 2010 to be uniform during the year

Table 1. Disease references used in the micro-simulation.

| DISEASE | SOURCE |
|---------|--------|
| CHD | Incidence: Epidemiology of acute myocardial infarction in Salvador, Brazil: Incidence, Lethality, and Mortality; Lessa I, Cortes E, Souza JA, Filho JS, Netto JP and Almeida FA; PAHO Bulletin 21(1), 1987 |
| | Mortality: Epidemiology of acute myocardial infarction in Salvador, Brazil: Incidence, Lethality, and Mortality; Lessa I, Cortes E, Souza JA, Filho JS, Netto JP and Almeida FA; PAHO Bulletin 21(1), 1987 |
| | Survival: Secular Trends in Cardiovascular Disease Mortality, Incidence, and Case Fatality rates in Adults in the United States; Ergin A, Muntner P, Sherwin R, He J, The American Journal of Medicine, 2004: 15; Vol. 117, pp. 219-227 |
| Cost | The burden of hospitalization due to overweight and obesity in Brazil; Sichieri R, Nascimento do S, Coutinho W; Cad. Saúde Pública, Rio de Janeiro, 2007; 23(7): 1721–1727 |
| Stroke | Incidence: Trends in stroke incidence, mortality and case fatality rates in Joinville, Brazil: 1995–2006; Cabral NL, Goncalves ARR, Longo AL, Moro CHC, Costa G, Amaral CH, Souza MV, Eluf-Neto J, Fonseca LAM; J Neurol Neurosurg Psychiatry 2009; 80: 749–754. doi:10.1136/jnnp.2008.164475 |
| | Mortality: Trends in stroke incidence, mortality and case fatality rates in Joinville, Brazil: 1995–2006; Cabral NL, Goncalves ARR, Longo AL, Moro CHC, Costa G, Amaral CH, Souza MV, Eluf-Neto J, Fonseca LAM; J Neurol Neurosurg Psychiatry 2009; 80: 749–754. doi:10.1136/jnnp.2008.164475 |
| | Survival: Stroke Incidence, Prognosis, 30-Day, and 1-Year Case Fatality Rates in Matao, Brazil: A Population-Based Prospective Study; Minelli C, Fu Fen L, Minelli DPC, 2007; Stroke: 30, 2906–2911 |
| Cost | The burden of hospitalization due to overweight and obesity in Brazil; Sichieri R, Nascimento do S, Coutinho W; Cad. Saúde Pública, Rio de Janeiro, 2007; 23(7): 1721–1727 |
| Hypertension | Prevalence: Hypertension Prevalence in the City of Formiga, MG (Brazil); de Castro RAA, Moncau JEC, Marcopito LF; Arq Bras Cardiol 2007; 88(3), pp.301-206 |
| | Cost: Estimated annual cost of arterial hypertension treatment in Brazil; Dib MW, Riera R and F MB, 2010; Rev Panam Salud Publica 27(2), pp.125–131 |
| Type 2 Diabetes | Prevalence: Prevalence of diabetes and hypertension based on self reported morbidity survey, Brazil 2006; Schmidt MI, Duncan BB, Hoffman JF, de Moura L, Malta DC, de Cavalho RMSV, Rev Saúde Pública 2009; 43(Supl. 2), pp. 1–8 |
| Knee Osteoarthritis | Prevalence: Used the USA figures as the proxy; Please see the methods section. |
| Cost | No costs were found. |
| All 8 Cancers | Incidence: Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 01/08/2011. |
| | Mortality: Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 01/08/2011. |
| | Cost of Breast and Colorectal Cancers: Breakaway: The global burden of cancer - challenges and opportunities; A report from the Economist Intelligence Unit; 2009; http://www.livestrong.org/pdfs/GlobalEconomicImpact |
| Cancer Survival | Colorectal Cancer survival in five continents: a worldwide population-based study (CONCORD). Coleman MP, Quaresma M, Berrino F, et al. Lancet Oncol. 2008 Aug; 9(8): 730–56 |
| | Breast: Five-year survival and prognostic factors in women with breast cancer in Santa Catarina State, Brazil. Schneider U, d’Orsi E. Cad Saude Publica. 2009 Jun; 25 (6): 1285-96. [Article in Portuguese] |
| | Endometrial: High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome. Viani GA, Patia BF, Pellizzon AC, De Melo MD, Novaes PE, Fogaroli RC, Conti MA, Salvajov JV. Radiat Oncol. 2006 Aug 3; 1: 24 |
| Other Cancers | Used the USA figures as the proxy; See the methods section. |

doi:10.1371/journal.pone.0068785.t001

Modelling

We employed the two-stage modelling process developed by the UK Foresight working group [37,38,39]. The software for this model was written in C++. The first module implements a regression analysis based on a series of cross-sectional data using a non-linear multivariate, categorical regression model and is designed to fit to the Brazilian BMI data series by age and sex. The second module implements a micro-simulation programme to produce longitudinal projections by creating a pseudo population cohort based on BMI distributions from module 1. Using a Monte-Carlo simulation method [40], diseases and their associated costs are probabilistically assigned each year as a function of the age, gender and BMI value for the simulated individual. The BMI trajectories are extrapolated using the simulation model with the assumption that an individuals’ BMI percentile in the same age cohort stays the same over time [20]. A simulated cohort member has a risk of getting an obesity-related disease each year if he or she is free of disease at the beginning of the year; the individuals continue living with the disease or die from it depending on disease characteristics (fatal or non- fatal). The progression of the diseases...
is defined by disease specific survival or case-fatality data, depending on available data. We simulated five million Brazilian individuals by sex and age. Country specific sex and age distributions are based on published projections from the UN Population database by year [41].

After projecting the BMI data forward to 2050, the disease burden associated with this trend has been calculated. The micro simulation enables us to estimate the health burden associated with the projected BMI trends and calculate economic constraints for any hypothetical policy or intervention scenarios in BMI development.

For this project, authors considered to evaluate disease and medical burden for three hypothetical scenarios. Scenario zero assumes no intervention and therefore obesity trends continue as predicted based on the previous pattern (intervention 0). In comparison, the two hypothetical policy scenarios are aiming to reduce the mean BMI by a constant percentage, either one (intervention 1) or 5% (intervention 2) across the whole population. In these two hypothetical interventions, the mean population BMI is reduced by 1% and 5% only in 2010 (a reference year), and the trend is projected from that decreased level forward. A similar method has been applied to Mexico [27] and other 10 countries in the Latin America [20], the Russian Federation [28], UK and US [19]. Further details of the two part modelling process can also be found in the Lancet and Tackling Obesities Report [19;37;38;39].

No future discounting rate has been applied to calculations since the cost projections are based on increased BMI trends itself and are not directly projected from the reference year cost (2010).

Results

BMI

As shown in Table 2 obesity rates are expected to increase for both males and females. In 2010, the model estimates that nearly 57% of the male population is overweight or obese (41% overweight and 16% obese). The rate is predicted to increase to 95% (49% overweight and 46% obese) by 2050. A smaller increase is expected among females, with 2010 rates estimated at 43% (29% overweight and 14% obese) increasing to 52% (32% overweight and 20% obese) by 2050.

Similar patterns are observed by age. Among men, the growth is found in all age groups. The increase is most prominent in men aged 25–49, and in older age groups, 70 and above. Generally, similar results are observed among females, but, in some age groups, the prevalence of normal weight is greater than that of obese and overweight. In 2030, the percent of females aged 40–49 that are normal weight is higher than the percent overweight and obese. Among the 30–39 year old age group the distribution varies. By 2030, the distribution among females aged 30–34 remains steady and slightly increases until age 39. After age 49, an increase in the BMI percentage is seen in all age groups (Table 3). By 2050 obesity and overweight overcome the normal weight 3–6 times in males in every age group, whereas in females, obesity rates are 1–3 times lower than normal weight with exception of age group 55–59 and 60–64 (Table 3). The detailed figures have been presented in File S1 as Figures S1–S24.

Diseases

High obesity rates have resulted in increased disease burden, causing significant increase in morbidity rate for all projected disease. Prevalence of CHD, stroke, 8 cancers, knee osteoarthritis and type 2 diabetes is projected to double between 2010 and 2050. The prevalence rate of hypertension is projected to reach over 34,000 in 2050 cases compared to 21,000 in 2010 (per 100,000). Prevalence of type 2 diabetes nearly doubles from 2010 to 2050 rising up to over 6,000 cases (per 100,000). Knee osteoarthritis is projected to double, whereas CHD, stroke and cancer prevalence cases will triple by 2050 (Table 4). The new cases of diseases also have been projected and can be found in File S3 as Table S3.

A 1% reduction in mean BMI would save over 15,000 prevalence cases in 2030 and nearly 10,000 cases in 2050 for cancers. The figures are even higher for CHD and stroke, the over 72,000 cases in 2030 and over 222,000 in 2050 (for whole Brazilian population). Over 0.7 million cases of knee osteoarthritis can be prevented with 1% reduction in BMI by 2050, whereas the figure for 2030 is over 72,000 in the whole population. Nearly 0.5 million cases of type 2 diabetes can be avoided with this intervention in 2030 and nearly 0.8 million cases in 2050. The avoided prevalence cases are highest for hypertension with over 1.2 million in 2030 and 1.6 million cases in 2050 being avoided in the total population.

The figures are even higher if mean BMI in the population decreased by 5%. The country could save nearly 6,000 cases of cancers in 2030 and over 21,000 in 2050. Over 310,000 and nearly 600,000 cases of CHD and stroke can be avoided in 2030 and 2050 respectively. 1.5 million and 2.5 million of knee osteoarthritis prevalence cases can be saved if BMI is reduced by 5%. Again, high numbers are observed for type 2 diabetes (1.1 million and 2.1 million in 2030 and 2050 respectively). Over 3.1 million cases of hypertension can be prevented in 2030, whereas this number can reach over 5.4 million in 2050 (per population). The figures have been presented per 100,000 of population in Table 5.

Costs

In the absence of intervention, obesity and overweight-related disease costs substantially increase between 2010 and 2050, increasing from $160 million to $313 million for female breast cancer in 2010 and 2050 respectively (US Dollars). The colorectal costs are expected to grow from $115 million to $214 million in the same time period. The costs of CHD and stroke more than double from 2010 to 2050 reaching $180 million for CHD in 2050 and $23 million for stroke. Hypertension medical costs are expected to increase from $445 million to $657 million in 2010 and 2050 alone. Diabetes imposes the highest health care expenditure, and it is projected to rise from $5 billion to $8.7 billion alone in 2010 and 2050 respectively. The costs have also been produced by gender and all are presented in Table 6.

A 1% reduction in mean BMI across the population will lead to reduction in health care expenditure. The total health care cost with no intervention was projected over $330 billion over 40 years (2010 to 2050). However, a 1% decrease in mean BMI will lead to saving of over $27 billion saving in the same time period, whereas this number will increase to over $36 billion from 2010 to 2050 with 5% decrease in mean BMI. The savings will reach over $10 billion for diabetes over 40 years by a 1% decrease in mean BMI and over $37 billion by a 5% reduction in mean BMI. A substantial reduction is also observed for hypertension, nearly $0.5 billion and $1.6 billion with a 1% and 5% reduction.

Limitations

Several limitations should be noted. The ability to obtain sex and age specific disease incidence data is limited, requiring the use of prevalence rates. For some calculations, we used proxy data (e.g., the US knee osteoarthritis data was applied to the Brazilian population) and limited accuracy. We have used CHD incidence data from 1982 and perhaps we have overestimated the burden of
the disease, since the incidence rates may be declining due to smoking reduction and enhancements in medical treatment. Survival data was also limited and therefore the rate from the US has been used. As noted before, the US has the highest health care expenditure per capita in the world \[31\], whereas Brazil spends nearly 8 times less than the US \[31\]. By using the figure from the US, we have probably overestimated survival for Brazil and depicted more optimistic outcomes. The analysis highlights the urgent need for better surveillance data in Brazil. Given the supposed overestimation of simulation, the forecasts for the real population would be expected to be even worse in terms of

| Year | MAles | BMI ≤24.9 kg/m² | BMI 25–30 kg/m² | BMI ≥30 kg/m² | Females | BMI ≤24.9 kg/m² | BMI 25–30 kg/m² | BMI ≥30 kg/m² |
|------|-------|----------------|----------------|--------------|---------|----------------|----------------|--------------|
| 2010 | 43    | 41             | 16             | 57           | 29      | 14             |                |              |
| 2011 | 42    | 42             | 16             | 57           | 29      | 14             |                |              |
| 2012 | 41    | 42             | 17             | 56           | 29      | 15             |                |              |
| 2013 | 39    | 43             | 18             | 56           | 29      | 15             |                |              |
| 2014 | 37    | 44             | 19             | 56           | 29      | 15             |                |              |
| 2015 | 36    | 44             | 20             | 56           | 29      | 15             |                |              |
| 2016 | 34    | 45             | 21             | 56           | 29      | 15             |                |              |
| 2017 | 33    | 46             | 21             | 56           | 29      | 15             |                |              |
| 2018 | 31    | 46             | 23             | 56           | 29      | 15             |                |              |
| 2019 | 30    | 47             | 23             | 55           | 30      | 15             |                |              |
| 2020 | 29    | 47             | 24             | 55           | 30      | 15             |                |              |
| 2021 | 27    | 48             | 25             | 55           | 30      | 15             |                |              |
| 2022 | 26    | 48             | 26             | 54           | 30      | 16             |                |              |
| 2023 | 25    | 48             | 27             | 54           | 30      | 16             |                |              |
| 2024 | 23    | 49             | 28             | 54           | 30      | 16             |                |              |
| 2025 | 22    | 49             | 29             | 54           | 30      | 16             |                |              |
| 2026 | 21    | 49             | 30             | 54           | 30      | 16             |                |              |
| 2027 | 20    | 50             | 30             | 54           | 30      | 16             |                |              |
| 2028 | 18    | 50             | 32             | 53           | 30      | 17             |                |              |
| 2029 | 17    | 50             | 33             | 53           | 30      | 17             |                |              |
| 2030 | 16    | 50             | 34             | 53           | 30      | 17             |                |              |
| 2031 | 16    | 50             | 34             | 52           | 31      | 17             |                |              |
| 2032 | 15    | 50             | 35             | 52           | 31      | 17             |                |              |
| 2033 | 14    | 50             | 36             | 52           | 31      | 17             |                |              |
| 2034 | 13    | 50             | 37             | 52           | 31      | 17             |                |              |
| 2035 | 12    | 50             | 38             | 52           | 31      | 17             |                |              |
| 2036 | 12    | 50             | 38             | 51           | 31      | 18             |                |              |
| 2037 | 11    | 50             | 39             | 51           | 31      | 18             |                |              |
| 2038 | 10    | 50             | 40             | 51           | 31      | 18             |                |              |
| 2039 | 10    | 50             | 40             | 51           | 31      | 18             |                |              |
| 2040 | 9     | 50             | 41             | 51           | 31      | 18             |                |              |
| 2041 | 8     | 50             | 42             | 50           | 31      | 19             |                |              |
| 2042 | 8     | 50             | 42             | 50           | 31      | 19             |                |              |
| 2043 | 7     | 50             | 43             | 50           | 31      | 19             |                |              |
| 2044 | 7     | 50             | 43             | 50           | 31      | 19             |                |              |
| 2045 | 6     | 50             | 44             | 49           | 32      | 19             |                |              |
| 2046 | 6     | 50             | 44             | 49           | 32      | 19             |                |              |
| 2047 | 6     | 50             | 44             | 49           | 32      | 19             |                |              |
| 2048 | 5     | 50             | 45             | 49           | 32      | 19             |                |              |
| 2049 | 5     | 50             | 45             | 48           | 32      | 20             |                |              |
| 2050 | 5     | 49             | 46             | 48           | 32      | 20             |                |              |
diseases burden. More accurate data will allow for more precise estimated in future work.

Brazil specific RR data was not accessible; therefore we have used the data for the European populations. Arguably, using a country specific RRs could change the picture, however, there is no evidence for Brazilian population RRs and we believe it is acceptable to use the data from Europe.

The data on total health care costs was also limited to a few diseases. Some cancer costs have not been found and therefore excluded from the projections. By including other disease costs, economic burden of obesity would be even higher. Though we have obtained costs of CHD, stroke, hypertension, diabetes and breast and colorectal cancers, the calculation methods were different among them. The CHD costs have been aggregated by summing up costs of IHD and MI costs and came from the same source as stroke [32]. However, the costs are likely to be underestimated since they are only hospitalization costs and only among adults of age 20–60 [32]. Projected costs of CHD and stroke, therefore, are very low for a county of its size and by using these inputs we could show the potential growth of the costs due to increased obesity rates. More precise costs should be used in future calculations when data become available.

We usually model type 2 diabetes, however, the costs used are for diabetes (direct cost of type 1 and type 2). This would not have a substantial impact on calculations, since type 1 diabetes only accounts for 5–10% of all diabetes diagnosed [42].

The economic burden of breast and colorectal cancers are also likely to be underestimated, since the input costs were only the costs of the new cases. Despite these limitations, cancers impose considerable monetary constrains on health care system. In the model, we only included medical costs; non-medical costs, such as productivity loss, have not been incorporated, and would substantially increase already high cost. Moreover, we have simulated only 13 diseases; other obesity-related conditions such as infertility [43] were not modelled which is likely to increase health care burden.

For this project, only adult BMI data has been used. Incorporating childhood trends could alter our projections. As is common, data on BMI is limited to self-reported surveys and, as noted elsewhere [44], individuals tend to underreport their weight. Using anthropometric data, rather than self-reported BMI data (as

Table 3. Projected distribution of BMI by age group and BMI group (%).

| Male | Age | 2010 | 2020 | 2030 | 2040 | 2050 |
|------|-----|------|------|------|------|------|
| BMI %| ≤24.9 | 25–29.9 | ≥30 | ≤24.9 | 25–29.9 | ≥30 | ≤24.9 | 25–29.9 | ≥30 | ≤24.9 | 25–29.9 | ≥30 | ≤24.9 | 25–29.9 | ≥30 |
| 20–24 | 62 | 29 | 8 | 43 | 40 | 17 | 25 | 46 | 29 | 12 | 48 | 40 | 6 | 48 | 46 |
| 25–29 | 48 | 39 | 13 | 30 | 48 | 22 | 16 | 52 | 32 | 8 | 52 | 40 | 4 | 51 | 46 |
| 30–34 | 41 | 43 | 16 | 25 | 49 | 26 | 14 | 51 | 36 | 7 | 50 | 43 | 4 | 49 | 48 |
| 35–39 | 39 | 43 | 18 | 25 | 48 | 27 | 12 | 51 | 35 | 8 | 50 | 42 | 4 | 50 | 46 |
| 40–44 | 37 | 45 | 18 | 25 | 49 | 26 | 16 | 51 | 34 | 9 | 51 | 40 | 5 | 50 | 45 |
| 45–49 | 36 | 44 | 2 | 23 | 49 | 28 | 13 | 51 | 35 | 7 | 51 | 42 | 4 | 50 | 46 |
| 50–54 | 36 | 43 | 2 | 23 | 46 | 30 | 14 | 47 | 39 | 8 | 46 | 46 | 4 | 46 | 50 |
| 55–59 | 53 | 26 | 44 | 19 | 34 | 24 | 56 | 26 | 14 | 53 | 33 | 8 | 53 | 39 | 4 | 53 | 43 |
| 60–64 | 38 | 44 | 18 | 25 | 48 | 27 | 14 | 50 | 36 | 8 | 49 | 43 | 4 | 48 | 48 |
| 65–69 | 44 | 42 | 14 | 30 | 50 | 20 | 18 | 57 | 25 | 10 | 59 | 31 | 6 | 59 | 36 |
| 70–74 | 44 | 43 | 13 | 30 | 48 | 22 | 18 | 51 | 31 | 10 | 51 | 39 | 6 | 50 | 45 |
| 75+ | 53 | 36 | 11 | 37 | 43 | 20 | 22 | 46 | 32 | 12 | 46 | 42 | 6 | 46 | 48 |

| Female | Age | 2010 | 2020 | 2030 | 2040 | 2050 |
|--------|-----|------|------|------|------|------|
| BMI % | ≤24.9 | 25–29.9 | ≥30 | ≤24.9 | 25–29.9 | ≥30 | ≤24.9 | 25–29.9 | ≥30 | ≤24.9 | 25–29.9 | ≥30 |
| 20–24 | 78 | 16 | 5 | 74 | 19 | 7 | 70 | 22 | 8 | 65 | 25 | 10 | 60 | 28 | 12 |
| 25–29 | 70 | 21 | 9 | 66 | 23 | 11 | 61 | 24 | 14 | 57 | 26 | 18 | 52 | 27 | 22 |
| 30–34 | 63 | 26 | 11 | 62 | 26 | 12 | 62 | 25 | 13 | 61 | 25 | 14 | 60 | 25 | 15 |
| 35–39 | 59 | 28 | 13 | 58 | 24 | 15 | 56 | 26 | 17 | 55 | 25 | 20 | 54 | 24 | 22 |
| 40–44 | 55 | 31 | 15 | 56 | 30 | 14 | 58 | 29 | 14 | 59 | 28 | 13 | 60 | 27 | 13 |
| 45–49 | 50 | 33 | 17 | 52 | 31 | 17 | 54 | 30 | 16 | 56 | 28 | 16 | 58 | 27 | 16 |
| 50–54 | 45 | 36 | 20 | 43 | 38 | 19 | 41 | 40 | 19 | 40 | 42 | 18 | 38 | 44 | 18 |
| 55–59 | 42 | 36 | 22 | 38 | 37 | 25 | 35 | 38 | 27 | 31 | 39 | 30 | 28 | 39 | 33 |
| 60–64 | 41 | 37 | 22 | 36 | 40 | 24 | 32 | 43 | 25 | 28 | 45 | 27 | 25 | 47 | 28 |
| 65–69 | 43 | 37 | 19 | 42 | 39 | 19 | 41 | 40 | 20 | 39 | 41 | 2 | 38 | 42 | 20 |
| 70–74 | 44 | 36 | 20 | 39 | 38 | 22 | 35 | 41 | 25 | 30 | 43 | 27 | 26 | 45 | 29 |
| 75+ | 49 | 33 | 18 | 42 | 36 | 22 | 35 | 39 | 26 | 28 | 42 | 30 | 23 | 43 | 34 |

doi:10.1371/journal.pone.0068785.t003
people tend to underreport their weight [45]) would increase the estimates. In addition, unlike the 1989 and 2003 data, which were nationally representative, the 2006–2010 VIGITEL data were only for cities. Using only urban data for BMI prevalence for the later years probably inflated the obesity growth, since urban areas in low and middle income nations experience growth in obesity before rural areas [46].

Table 4. Prevalence cases for all adults (per 100,000). The numbers in square brackets represent confidence intervals.

| Intervention 0 | Year | 8 Cancers | CHD & Stroke | Knee Osteoarthritis | Type 2 Diabetes | Hypertension |
|----------------|------|-----------|--------------|--------------------|-----------------|-------------|
|                | 2010 | 281 [±5]  | 1,155 [±10] | 12,728 [±32]      | 3,079 [±16]     | 21,064 [±41] |
|                | 2020 | 379 [±5]  | 1,664 [±11] | 15,107 [±34]      | 3,799 [±17]     | 25,066 [±43] |
|                | 2030 | 463 [±6]  | 2,109 [±12] | 17,755 [±36]      | 4,557 [±18]     | 28,824 [±46] |
|                | 2040 | 548 [±6]  | 2,635 [±14] | 20,320 [±38]      | 5,345 [±20]     | 31,999 [±48] |
|                | 2050 | 615 [±7]  | 3,148 [±15] | 22,393 [±41]      | 6,009 [±21]     | 34,336 [±51] |

| Intervention 1 | Year | 8 Cancers | CHD & Stroke | Knee Osteoarthritis | Type 2 Diabetes | Hypertension |
|----------------|------|-----------|--------------|--------------------|-----------------|-------------|
|                | 2010 | 280 [±5]  | 1,149 [±10] | 12,757 [±32]      | 3,075 [±16]     | 21,053 [±41] |
|                | 2020 | 378 [±5]  | 1,635 [±11] | 14,968 [±34]      | 3,678 [±17]     | 24,724 [±43] |
|                | 2030 | 455 [±6]  | 2,072 [±12] | 17,484 [±36]      | 4,338 [±18]     | 26,206 [±45] |
|                | 2040 | 539 [±6]  | 2,570 [±14] | 19,989 [±38]      | 4,992 [±19]     | 31,219 [±48] |
|                | 2050 | 610 [±7]  | 3,035 [±15] | 21,988 [±40]      | 5,540 [±20]     | 33,483 [±50] |

| Intervention 2 | Year | 8 Cancers | CHD & Stroke | Knee Osteoarthritis | Type 2 Diabetes | Hypertension |
|----------------|------|-----------|--------------|--------------------|-----------------|-------------|
|                | 2010 | 278 [±5]  | 1,151 [±10] | 12,729 [±32]      | 3,075 [±16]     | 21,046 [±41] |
|                | 2020 | 370 [±5]  | 1,568 [±11] | 14,602 [±33]      | 3,456 [±16]     | 24,204 [±43] |
|                | 2030 | 451 [±6]  | 1,951 [±12] | 16,977 [±35]      | 3,951 [±17]     | 27,222 [±44] |
|                | 2040 | 534 [±6]  | 2,426 [±13] | 19,305 [±37]      | 4,476 [±18]     | 29,741 [±46] |
|                | 2050 | 604 [±7]  | 2,889 [±15] | 21,112 [±40]      | 4,900 [±19]     | 31,568 [±48] |


table0

Table 5. Prevalence cases avoided from year 2010 by interventions (per 100,000 of population in 2010).

| Intervention 1 | Year | 8 Cancers | CHD & Stroke | Knee Osteoarthritis | Type 2 Diabetes | Hypertension |
|----------------|------|-----------|--------------|--------------------|-----------------|-------------|
|                | 2010 | 1 [±7]    | 6 [±14]      | 0 [±45]            | 4 [±22]         | 11 [±58]    |
|                | 2020 | 1 [±8]    | 29 [±16]     | 139 [±49]          | 121 [±24]       | 342 [±63]   |
|                | 2030 | 8 [±9]    | 37 [±18]     | 271 [±53]          | 219 [±37]       | 618 [±68]   |
|                | 2040 | 9 [±9]    | 84 [±20]     | 331 [±57]          | 353 [±29]       | 780 [±71]   |
|                | 2050 | 5 [±10]   | 113 [±22]    | 405 [±60]          | 469 [±30]       | 853 [±74]   |

| Intervention 2 | Year | 8 Cancers | CHD & Stroke | Knee Osteoarthritis | Type 2 Diabetes | Hypertension |
|----------------|------|-----------|--------------|--------------------|-----------------|-------------|
|                | 2010 | 3 [±7]    | 4 [±14]      | 0 [±45]            | 4 [±22]         | 18 [±58]    |
|                | 2020 | 9 [±8]    | 96 [±16]     | 505 [±49]          | 343 [±24]       | 862 [±63]   |
|                | 2030 | 12 [±9]   | 158 [±18]    | 778 [±53]          | 606 [±26]       | 1,602 [±67] |
|                | 2040 | 14 [±9]   | 228 [±20]    | 1,015 [±56]        | 869 [±28]       | 2,258 [±70] |
|                | 2050 | 11 [±10]  | 289 [±22]    | 1,281 [±59]        | 1,109 [±30]     | 2,768 [±73] |

The numbers in square brackets represent confidence intervals.

Adult Obesity in Brazil

doi:10.1371/journal.pone.0068785.t004

Intervention 0– BMI projections according to the past trend; Intervention 1–1% reduction in BMI across the population in 2010; Intervention 2–5% reduction in BMI across the population in 2010.
doi:10.1371/journal.pone.0068785.t005

Intervention 0– BMI projections according to the past trend; Intervention 1–1% reduction in BMI across the population in 2010; Intervention 2–5% reduction in BMI across the population in 2010.
doi:10.1371/journal.pone.0068785.t006
Conclusion

Our analysis shows that the percentage of overweight and obesity and the associated disease and economic burden will substantially increase in Brazil. The increase will be higher among men than among women. Arguably, lower rates of obesity among women can be linked to an increased underreporting from females [45]. Importantly, decrease has been observed in the past among females of urban areas of Brazil [17,18] and BMI projections for this paper are drawn from the data from urban region of Brazil.

Table 6. Estimated disease costs according to the hypothetical scenarios.

| Year | Breast* | Colorectal | Cancers | Cardio Vascular Diseases | Total |
|------|---------|------------|---------|---------------------------|-------|
| 2010 | 160     | 115        | 81      | 9                         | 445   | 5,005 | 5,815 |
| 2015 | 183     | 124        | 97      | 12                        | 485   | 5,551 | 6,452 |
| 2020 | 203     | 135        | 110     | 13                        | 519   | 5,997 | 6,977 |
| 2025 | 223     | 155        | 123     | 14                        | 550   | 6,443 | 7,508 |
| 2030 | 244     | 167        | 134     | 15                        | 579   | 6,944 | 8,083 |
| 2035 | 266     | 179        | 146     | 18                        | 603   | 7,439 | 8,651 |
| 2040 | 285     | 192        | 157     | 19                        | 624   | 7,888 | 9,165 |
| 2045 | 302     | 204        | 171     | 22                        | 642   | 8,327 | 9,667 |
| 2050 | 313     | 214        | 180     | 23                        | 657   | 8,718 | 10,106|
| 2010–2050 | 9,950 | 6,753 | 5,490 | 667 | 23,326 | 284,261 | 330,447 |

| Year | Breast* | Colorectal | Cancers | Cardio Vascular Diseases | Total |
|------|---------|------------|---------|---------------------------|-------|
| 2010 | 160     | 115        | 81      | 9                         | 445   | 5,005 | 5,540 |
| 2015 | 181     | 128        | 96      | 12                        | 482   | 5,480 | 6,069 |
| 2020 | 203     | 135        | 108     | 13                        | 513   | 5,866 | 6,500 |
| 2025 | 223     | 149        | 119     | 14                        | 542   | 6,276 | 6,951 |
| 2030 | 245     | 165        | 129     | 15                        | 568   | 6,713 | 7,425 |
| 2035 | 266     | 168        | 141     | 18                        | 590   | 7,129 | 7,878 |
| 2040 | 283     | 186        | 152     | 19                        | 608   | 7,517 | 8,296 |
| 2045 | 298     | 200        | 162     | 22                        | 624   | 7,874 | 8,682 |
| 2050 | 310     | 212        | 171     | 23                        | 637   | 8,169 | 9,000 |
| 2010–2050 | 9,907 | 6,649 | 5,285 | 661 | 22,894 | 273,964 | 302,803 |

| Year | Breast* | Colorectal | Cancers | Cardio Vascular Diseases | Total |
|------|---------|------------|---------|---------------------------|-------|
| 2010 | 160     | 115        | 81      | 9                         | 445   | 5,005 | 5,540 |
| 2015 | 180     | 132        | 91      | 12                        | 475   | 5,236 | 5,813 |
| 2020 | 202     | 150        | 99      | 13                        | 501   | 5,453 | 6,066 |
| 2025 | 220     | 143        | 108     | 14                        | 523   | 5,706 | 6,351 |
| 2030 | 241     | 156        | 118     | 15                        | 542   | 6,002 | 6,677 |
| 2035 | 264     | 187        | 126     | 17                        | 556   | 6,314 | 7,013 |
| 2040 | 283     | 197        | 135     | 18                        | 566   | 6,593 | 7,312 |
| 2045 | 298     | 207        | 144     | 21                        | 572   | 6,830 | 7,566 |
| 2050 | 309     | 216        | 151     | 22                        | 575   | 6,962 | 7,710 |
| 2010–2050 | 9,861 | 6,912 | 4,812 | 629 | 21,755 | 246,672 | 273,868 |

*Females only;  
**The numbers do not sum up since this is a total cost from 2010–2050 whereas other costs represent the actual cost in a particular year.

doi:10.1371/journal.pone.0068785.t006
This is also likely to have influenced presented obesity levels among women. Further research is needed to examine the possible reasons for gender differences.

The obesity increase is very likely to be linked to increased consumption of ultra-processed food which is a source of cheaper calories, sedentary lifestyle and/or economic transition. In turn, high obesity rates are drivers of increased NCDs morbidity rates, as well as higher costs for the healthcare system. Our analysis shows that even relatively small reductions in the level of BMI can lead to a substantial disease in the reduction and cost savings for the health care system. These results also can be translated to average costs per case and can be used in cost-effectiveness analysis for comparing programs and policies affecting obesity in Brazil.

Projected high burden of disease shows that a crucial change in policies is needed to tackle and avoid high rates of diseases and health care costs. Due to increased prevalence rates in weight gain and sedentary behaviour, some steps have been made in late 90 s. In 1996, with the financial support from the Health Secretariat of the state of Sao Paulo, the physical activity program – Agita, the program promoting adoption of physical activity was launched. As a result, physical activity among students, workers and the elderly increased, and the program has been considered as a model for other developing countries by the WHO [47]. The food marketing restrictions have been also advocated by various agencies, however it was regarded as ‘unconstitutional’ (pg.31) and did not come into force [48].

Our model shows that a 1% reduction in the mean BMI alone can lead to a large change in NCD rates. These attenuated trends can be accomplished by either prevention (of weight gain) or weight reduction interventions across the whole population. The OECD has assessed some prevention programmes for Mexico and concluded that they are all cost-effective, some with an immediate effectiveness and some over the long term [49] and similar method can be applied to Brazil. Gortmaker and colleagues [50] recommend multiple policy recommendations for preventing and controlling obesity that may also be applicable to countries such as Brazil. A 5% reduction will be more difficult to accomplish, however, we believe it is achievable with thorough planning and stronger policy. It would require different stakeholders to work along and strong leadership from health care community and government willingness to tackle high rates of morbidity and NCD mortality in Brazil. A more comprehensive policy approach, better surveillance data on health care resources and continued evaluation of policies will be needed to ensure their success in Brazil.

Several limitations have been drawn in the previous section. As noted, multiple disease costs have not been found, therefore incorporating them into the model, along with other conditions (except these 13 diseases) will, however, increase economic constraints. Economic burden is likely to increase by incorporating non-medical costs. Lack of measured BMI data, outdated disease incidence rates, absence of healthcare costs for multiple conditions, as well as utilization of survival figures from other countries can lead to inaccuracy in presenting the projected data. However, we believe that our projections are timely and draw attention of the policy makers to important issues rising in Brazil. Our approach is conservative, and incorporating more comprehensive data will more likely increase projected disease burden.

**Supporting Information**

**File S1** Figure S1-S24 Distribution of the BMI (kg/m²) among males and females aged 20–75+. (DOC)

**File S2** Table S2 Cost input in the model. (DOC)

**File S3** Table S3 Cumulative incidence cases by intervention. (DOC)

**Acknowledgments**

The authors would like to thank the Pan American Health Organization, Renata Yokota, Deborah Carvalho Malta and Carlos A. Monteiro.

**Author Contributions**

Conceived and designed the experiments: KR TM MB KM. Performed the experiments: KR TM LW FK MB KM. Analyzed the data: KR. Contributed reagents/materials/analysis tools: KR DL WC MB. Wrote the paper: KR TM LW DL.

**References**

1. The World Health Organization (1995) Preventing Chronic Diseases: A Vital Investment. Geneva; vi–33.
2. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT et al (2011) The global obesity pandemics: shaped by global drivers and local environments; The Lancet 378: 804–814.
3. The World Health Organization (2009) World Health organisation Statistics 2009. Geneva; 7–142; http://www.who.int/gho/publications/world_health_statistics/EN_WHS09_Full.pdf.
4. Schmidt MI, Duncan BB, Silva GA, Menezes AM, Monteiro CA et al (2011) Chronic non-communicable diseases in Brazil: burden and current changes. The Lancet 357: 1949–1961.
5. Lotufo PA (2000) Increasing Obesity in Brazil: Prediction a New Peak of Cardiovascular Mortality. Sao Paulo Medical Journal 118: 161–162.
6. The United Nations Department of Economic and Social Affairs; Population Division (2002) World Population Aging. 1950–2050. New York; 1–37.
7. Nooyens AGJ, Vischel TLS, Verschuren WWM Schuit AJ, Boshuizen HC et al (2008) Age, period and cohort effects of body mass weight and body mass index in adults: The Doetinchem Cohort Study. Public Health Nutrition 12: 862–870.
8. Monteiro CA, Mounini L, de Souza AL, Popkin BM (1995) The nutrition transition in Brazil. European Journal of Clinical Nutrition 49: 105–113.
9. Drewnowski A, Popkin BM (1997) The Nutrition Transition: New Trends in the Global Diet. Nutrition Reviews 55: 31–43.
10. Popkin BM (1994) The Nutrition Transition in Low-Income Countries: An Emerging Crisis. Nutrition Reviews 52: 285–298.
11. Monteiro CA, Levy RB, Claro RM, Castro IR, Cannon G (2010) Increasing obesity of ultra-processed foods and likely impact on human health: evidence from Brazil. Public Health Nutrition 14: 5–13.
12. Monteiro CA, Cannon G (2012) The Impact of Transitional “Big Food” Companies on the South: A View from Brazil. PLoS Medicine 9: 1–5.
13. Monteiro CA (2010) The big issue is ultra-processing. Journal of the World Public Health Nutrition Association 6 http://www.wphna.org/win_commentary_ultraprocessing_nov2010.asp.
14. Levy RB, Claro RM, Mounini L, Sichieri R, Monteiro CA (2012) Regional and socioeconomic distribution of household food availability in Brazil, in 2008–2009. Revista Saude Publica 46: 1–9.
15. Stuckler D, McKee M, Ebrahim Sh, Basu S (2012) Manufacturing Epidemics: The Role of Global Producers in increased Consumption of Unhealthy Commodities Including Processed Foods, Alcohol and Tobacco. PLoS Medicine 9: 1–8.
16. Webb P, Block S (2010) Support for agriculture during economic transformation: Impacts on poverty and undernutrition. PNAS 1: 1–6.
17. Monteiro CA, Benicio MH, Conde WL, Popkin BM (2000) Shifting obesity trends in Brazil. European Journal of Clinical Nutrition 54: 342–346.
18. Monteiro CA, Conde WL, Popkin BM (2007) Income-Specific Trends in Obesity in Brazil: 1975–2003. American Journal of Public Health 97: 1808–1812.
19. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M (2011) Health and economic burden of the projected obesity trends in the USA and the UK. The Lancet 378: 813–823.
20. Webber L, Kipli F, Marsh T, Rviladze K, Brown M et al (2012) High Rates of Obesity and Non-Communicable Diseases Predicted across Latin America. PLoS One 7: 1–6.
31. The World Health Organization; Global Health Observatory Data Repository.

30. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr [Accessed on 01/06/2011].

29. Rtveladze K, Marsh T, Barquera S, Sanchez Romero LM, Levy D et al (2013) Obesity Trends in Russia. The impact on health and healthcare costs. Health 2: 1471–1481.

28. The World Health Organization. Body mass index – BMI, http://www.euro.who.int/en/what-we-do/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi [Accessed on 01/06/2011].

27. Lobstein T, Leach RJ (2009) Data documentation for the Dynamic Modelling software/en/ [Accessed on 01/06/2011].

26. Lobstein T, Leach RJ (2009) Data documentation for the Dynamic Modelling for Health Impact Assessment (DYNAMO-HIA) Project. Workpackage 7: Overweight and obesity report on data collection for overweight and obesity prevalence and related relative risks; I. 2009: 1–98.

25. The World Health Organization. Body mass index – BMI, http://www.euro.who.int/en/what-we-do/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi [Accessed on 01/06/2011].

24. Moura EC, Malta D, Morais Neto OLD, Moteiro CA (2009) Prevalence and social distribution of risk factors for chronic noncommunicable diseases in Brazil. Revista Panamericana de Salud Publica 25: 17–22.

23. Barreto SM, de Figueiredo RC (2009) Chronic diseases, self-perceived health status and health risk behaviours: gender differences. Revista Saude Publica 32: 1–9.

22. Ministério da Saúde Brasil. VIGITEL Brazil 2006/2007: Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico, Brasília; 1–302 http://portal.saude.gov.br/portal/arquivos/pdf/vigi_tel_2006_brasil.pdf.

21. Webber L, Kiliç F, Marsh T, Rtveladze K, McPherson K et al (2012) Modelling obesity trends and related diseases in Eastern Europe. Obesity Reviews 13: 751–761.

20. Webber L, Kiliç F, Marsh T, Rtveladze K, McPherson K et al (2012) Modelling obesity trends and related diseases in Eastern Europe. Obesity Reviews 13: 751–761.

19. Butland B, Jebb S, Kopelman P, McPherson K, Thomas S et al (2007) Foresight Tackling Obesities: Future Choices - Project report. London: Government Office for Science; 1–161.

18. Kopelman P, Jebb SA, Butland B (2007) Executive summary: Foresight ‘Tackling Obesities: Future Choices’ project. Obesity Reviews 8: vi–ix.

17. Rtveladze K, Marsh T, Webber L, Goryakin Ye et al (2013) Obesity Prevalence in Mexico, Impact on Health and Economic Burden. Public Health Nutrition 1: 1–7.

16. The World Health Organization. Health statistics and health information; Software tools. http://www.who.int/healthinfo/global_burden_disease/tools_/software/en/ [Accessed on 01/06/2011].

15. Butland B, Marsh T, Barquera S, Sanchez Romero LM, Levy D et al (2013) Obesity trends in Russia. The impact on health and healthcare costs. Health 2: 1471–1481.

14. Macdiarmid J, Blundell J (1998) Assessing dietary intake: Who, what and why of under-reporting; Nutrition Research Reviews 11: 231–253.

13. Visscher TLS, Lucie A, Kroesbergen HT, Seidell JC (2006) Underreporting of BMI in Adults and Its Effect on Obesity Prevalence Estimations in the Period 1990 to 2001. Obesity 14: 2053–2063.

12. Fishman GS (1995) Monte Carlo concepts, algorithms, and applications. Springer: New York, USA.

11. Hawkes C (2007) Marketing Food to Children: Changes in the Global Regulatory Environment 2004–2006; The World Health Organization; 1–96.

10. Dib MW, Riera R, F MB (2010) Estimated annual cost of arterial hypertension treatment in Brazil; Rev Panam Salud Publica 27(2): 125–131.

9. Ministry of Health Brazil. VIGITEL Brazil 2006/2007: Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico, Brasília; 1–302 http://portal.saude.gov.br/portal/arquivos/pdf/vigi_tel_2006_brasil.pdf.

8. Barcelo A, Aedo C, Rajpathak S, Robles S (2003) The cost of diabetes in Latin America and the Caribbean; Bulletin of the World Health Organization 81: 19–23.

7. National Diabetes Education Program (NDEP); National Institutes of Health: US Department of Health and Human Services; http://diabetes.niddk.nih.gov/dm/pubs/overview/ [Accessed December 2012].

6. Bureau of Labor Statistics, United States Department of Labor; Inflation Calculator; http://www.bls.gov/data/inflation_calculator.htm [Accessed December 2012].

5. Bright J, Lawrence J, Viner RM (2005) Comprehensive obesity prevention policy: the need for multidisciplinary action. European Child & Adolescent Psychiatry 14: 265–272.

4. Barreto SM, de Figueiredo RC (2009) Chronic diseases, self-perceived health status and health risk behaviours: gender differences. Revista Saude Publica 32: 1–9.

3. McPherson K, Marsh T, Brown M (2007) Tackling Obesities: Future Choices - Project report. London: Government Office for Science; 1–71.

2. McPherson K, Marsh T, Brown M (2007) Tackling Obesities: Future choices - Modelling Future Trends in Obesity & the Impact on Health. London: Government Office for Science; 1–71.

1. Butland B, Marsh T, Barquera S, Sanchez Romero LM, Levy D et al (2013) Obesity Prevalence in Mexico, Impact on Health and Economic Burden. Public Health Nutrition 1: 1–7.